Advertisement

Topics

Cytotoxic drugs - Biotech, Pharma and Life Science Channel

13:54 EST 23rd January 2017 | BioPortfolio

PubMed Articles [5713 Associated PubMed Articles listed on BioPortfolio]

Synthesis of new pyridothienopyrimidinone derivatives as Pim-1 inhibitors.

Four series of pyridothienopyrimidin-4-one derivatives were designed and prepared to improve the pim-1 inhibitory activity of the previously reported thieno[2,3-b]pyridines. Significant improvement in...

Methanethiosulfonate derivatives as ligands of the STAT3-SH2 domain.

With the aim to discover new STAT3 direct inhibitors, potentially useful as anticancer agents, a set of methanethiosulfonate drug hybrids were synthesized. The in vitro tests showed that all the thios...

Non-invasive Photodynamic Therapy in Brain Cancer by Use of Tb(3+)-Doped LaF3 Nanoparticles in Combination with Photosensitizer Through X-ray Irradiation: A Proof-of-Concept Study.

The use of photodynamic therapy (PDT) in the treatment of brain cancer has produced exciting results in clinical trials over the past decade. PDT is based on the concept that a photosensitizer exposed...

Fullerene C60 Penetration into Leukemic Cells and Its Photoinduced Cytotoxic Effects.

Fullerene C60 as a representative of carbon nanocompounds is suggested to be promising agent for application in photodynamic therapy due to its unique physicochemical properties. The goal of this stud...

Biosynthesis, Characterization, and Bioactivities Evaluation of Silver and Gold Nanoparticles Mediated by the Roots of Chinese Herbal Angelica pubescens Maxim.

A facile synthesis and biological applications of silver (DH-AgNps) and gold nanoparticles (DH-AuNps) mediated by the aqueous extract of Angelicae Pubescentis Radix (Du Huo) are explored. Du Huo is a ...

Conjugation site analysis of antibody-drug-conjugates (ADCs) by signature ion fingerprinting and normalized area quantitation approach using nano-liquid chromatography coupled to high resolution mass spectrometry.

Trastuzumab-MCC-DM1 (T-DM1) is an antibody-drug conjugate (ADC) that consists of a monoclonal antibody (mAb) trastuzumab non-cleavably linked to a cytotoxic drug DM1. During production, the DM1 agents...

Delivering on Antimicrobial Resistance Agenda Not Possible without Improving Fungal Diagnostic Capabilities.

Antimicrobial resistance, a major public health concern, largely arises from excess use of antibacterial and antifungal drugs. Lack of routine diagnostic testing for fungal diseases exacerbates the pr...

Baseline General Characteristics of the Korean Chronic Kidney Disease: Report from the KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease (KNOW-CKD).

The KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease (KNOW-CKD) was developed to investigate various clinical courses and risk factors for progression of Korean chronic kidney ...

Epithelial-to-Mesenchymal Transition in Paclitaxel-Resistant Ovarian Cancer Cells Is Downregulated by Luteolin.

Ovarian cancer (OVCA) is the deadliest of all gynecological cancers which is attributed to late presentation, persistence, and development of chemoresistance. The objectives were to evaluate the assoc...

Flavopiridol: An Old Drug With New Perspectives? Implication for Development of New Drugs.

Glioblastoma, the most common brain tumor, is characterized by high proliferation rate, invasion, angiogenesis, and chemo- and radio-resistance. One of most remarkable feature of glioblastoma is the s...

News Articles [5501 Associated News Articles listed on BioPortfolio]

Winning design: Designing drugs for better patient adherence

Chris Halling, director, global communications & marketing at Catalent writes about how drug design affects patient adherence.

India issues guidelines for the sale of antibiotics

The recent death of a woman, who died after contracting an antibiotic-resistant infection has caused the Drugs Controller General of India (DCGI) to issue strict guidelines on the selling of antibioti...

Enanta Pharmaceuticals to Host Conference Call on February 8 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal First Quarter Ended December 31, 2016

Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver di...

I Do Hate To Tell You This, But. . .

The timing of this report from the FDA is surely no accident, but it’s always a good time to think about this: the great majority of all drugs that enter clinical trials fail. They fail because ...

FDA proposal to regulate gene edited animals is ‘nonsensical’

UC Davis animal geneticist Alison Van Eenennaam challenges the FDA's proposal to regulate genetic modification of animals the same way it does drugs. Unless the proposal is changed, animal breeders' ...

Extending Rx exclusivity could boost study for rare diseases

(HealthDay)—Extending the market exclusivity for existing drugs that are granted subsequent U.S. Food and Drug Administration (FDA) approval for a new rare disease indication would provide manufactu...

Hope Biosciences Licenses nuc-Gemcitabine, A 'Trojan Horse' Anti-nucleolin-Gemcitabine Aptamer Drug Conjugate Against Cancer

IRVINE, Calif., Jan. 23, 2017 /PRNewswire/ -- HOPE BIOSCIENCES announced today that it has acquired the exclusive rights to develop and commercialize nuc-gemcitabine™ (APTA-12/HOPE-888) through...

UPDATE 2-Poor countries allowed to import generic drugs - WTO

GENEVA, Jan 23 (Reuters) - Poor countries are allowed to import generic medicines, World Trade Organization (WTO) Director General Roberto Azevedo told Reuters on Monday, after the required two-thirds...

Breast cancer drugs stop working when tumors 'make their own fuel'

The early-stage findings, from an international team led by Imperial College London and the European Institute of Oncology in Milan, reveal some breast tumours evolve to make their own 'fuel supply', ...

Actelion misses goal in study, but takeover talks likely unaffected

Pharma giant J&J is in exclusive discussions with Actelion about a potential acquisition of the Swiss biotech and its portfolio of drugs for pulmonary hypertension. 

Events [0 Results]

None

Companies [277 Associated Companies listed on BioPortfolio]

Decibel Therapeutics

By combining recent innovations in hearing science with leading diagnostic tools, biological insights, modeling and therapeutic delivery techniques, Decibel is pioneering a compre...

Neurotechnology Industry Organization

The Neurotechnology Industry Organization is the trade association that represents companies involved in neuroscience including software, drugs, devices, and diagnostics, brain re...

Reset Therapeutics, Inc.

Reset, a discovery-stage biopharma company co-founded by leaders in the field of circadian biology and Bay City Capital, is developing first-in-class approaches to treating diseas...

SciFluor Life Sciences, Inc.

SciFluor Life Sciences is a drug discovery company developing a best-in-class portfolio of partnership-ready therapeutic drugs strategically capitalizing on the transformational p...

Altan Pharma Limited

Altan Pharma Ltd. is a privately held, specialty pharmaceutical company that develops, manufactures and commercialises injectable drugs for the hospital and other provider segm...

Ensemble Therapeutics

EnsemblinsTM are a new class of synthetic macrocycles developed by Ensemble using its proprietary chemistry platforms, including DNA-Programmed ChemistryTM. Macrocyc...

XenoPort

We are a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates for the potential treatment of central nervous system (CNS) disorders. We also have a p...

Verseon

Verseon is a technology-based pharmaceutical company that employs its proprietary computational drug discovery platform to develop novel therapeutics for today’s challenging ...

Enable Injections

Founded February 2010 by medical device industry veterans, Cincinnati, OH-based Enable Injections develops and manufactures devices that allow easy, comfortable patient self-admin...

Icagen, Inc.

Icagen, Inc. is a biopharmaceutical company based in Research Triangle Park, North Carolina, focused on the discovery, development and commercialization of novel orally-administered small molecule...

Clinical Trials [1059 Associated Clinical Trials listed on BioPortfolio]

A Novel Surgical Method in the Treatment of Unstable Vitiligo

Vitiligo is a complex disease causing a selective, often progressive, loss of functioning melanocytes from epidermal basal layer resulting in white patches on the skin and occasionally muc...

A Single-center Clinical Trial of Bortezomib in Management of Immune Thrombocytopenia (ITP)

Primary immune thrombocytopenia (ITP) is a disorder caused by autoantibody-mediated platelet destruction and decreased platelet production. It has been reported that refractory ITP is clos...

Combination of Radiation Therapy and Peptide Specific CTL Therapy in Treating Patients With Esophageal Cancer

Immunotherapy is now considered to be one of promising approaches for treating cancer. Radiation therapy has been to be a cornerstone treatment for unresectable advanced esophageal cancer....

CMV-CTL for the Treatment of CMV Infection After HSCT

Human cytomegalovirus (CMV) infection is a major cause of morbidity and mortality for recipients of allogeneic hematopoietic stem cell transplantation(HSCT). we propose to study the immuno...

CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia

The investigators hypothesize that CX-01 will disrupt the bone marrow microenvironment and increase the cytotoxic effects of azacitidine on myelodysplastic syndrome (MDS) and acute myeloid...

Atezolizumab With Stereotactic Ablative Radiotherapy in Patients With Metastatic Tumours

Although it is usually described as an immunosuppressive modality and not thought of as immunotherapy, there are new preclinical evidences suggesting that high-dose ionizing irradiation (I...

Impact of HLA-E Overexpression by Tumor Cells on the Biology of TIL in Colorectal Cancer

Accumulating evidences suggest that colorectal cancer (CRC) progression is not solely determined by the genetic abnormalities of the tumor cells but also by the host response. Indeed, rece...

Nivolumab With Epstein Barr Virus Specific T Cells (EB-VSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE)

Subjects have a type of a lymph node cancer called Non-Hodgkin's Lymphoma (NHL) or lymphoproliferative disease (LPD), which affects their immunity, blood production, and can involve multip...

Self-monitoring and Reminder Texts to Increase Physical Activity After Cancer: a Pilot Randomized Controlled Trial

Epidemiologic data consistently indicate that colorectal cancer survivors can improve their quality-of-life and prognosis by engaging in physical activity. This study aims to build on this...

Treatment of Metastatic Melanoma With TSA-CTL(Tumor Specific Antigen-Induced Cytotoxic T Lymphocytes)

The primary purpose of this study is to evaluate the safety of TSA-CTL in the treatment of the advanced melanoma. The secondary purpose of this study is to evaluate preliminarily the effe...

Videos

None available.

Medical and Biotech [MESH] Definitions

A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.

A cytokine which resembles IL-1 structurally and IL-12 functionally. It enhances the cytotoxic activity of NK CELLS and CYTOTOXIC T-LYMPHOCYTES, and appears to play a role both as neuroimmunomodulator and in the induction of mucosal immunity.

Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals.

A critical subpopulation of regulatory T-lymphocytes involved in MHC Class I-restricted interactions. They include both cytotoxic T-lymphocytes (T-LYMPHOCYTES, CYTOTOXIC) and CD8+ suppressor T-lymphocytes.

Drugs used by veterinarians in the treatment of animal diseases. The veterinarian's pharmacological armamentarium is the counterpart of drugs treating human diseases, with dosage and administration adjusted to the size, weight, disease, and idiosyncrasies of the species. In the United States most drugs are subject to federal regulations with special reference to the safety of drugs and residues in edible animal products.

Quick Search
Advertisement
 
review and buy Cytotoxic drugs market research data and corporate reports here

Channels Quicklinks